Alzheimer’s drug bites the dust; Re­struc­ture, re­struc­ture, re­struc­ture; Land­mark di­a­betes OK; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be­ing in the news busi­ness can give one a warped sense of time — it feels like quite a while since we pub­lished some of these sto­ries be­low. But next Sat­ur­day’s End­points Week­ly will def­i­nite­ly be short­er, as we take off Thurs­day and Fri­day for Thanks­giv­ing. We will still have the ab­bre­vi­at­ed edi­tion in your in­box at the usu­al time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER